Woo Hyun Young, Han Sung Yong, Heo Jeong, Kim Dong Uk, Baek Dong Hoon, Yoo So Yong, Kim Chang Won, Kim Suk, Song Geun Am, Cho Mong, Kang Dae Hwan
Department of Internal Medicine, College of Medicine and Medical Research Institute, Pusan National University, Pusan National University Hospital, Busan, Republic of Korea.
Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
PLoS One. 2017 Nov 2;12(11):e0187469. doi: 10.1371/journal.pone.0187469. eCollection 2017.
Patients with advanced hepatocellular carcinoma (HCC) with jaundice have an extremely poor prognosis. Although biliary drainage can resolve obstructive jaundice, signs of obstruction may not be evident. This study evaluated the role of endoscopic biliary drainage in patients with advanced HCC and obstructive jaundice.
From 2010 to 2015, 74 patients underwent endoscopic biliary drainage for obstructive jaundice due to advanced HCC. Jaundice resolution was defined as complete response and total bilirubin concentration below 3 mg/dl.
The technical success rate in the 74 patients was 92.1% (70/76). Of the 70 patients who underwent successful biliary drainage, 48 (68.6%) and 22 (31.4%) were Child-Pugh classes B and C, respectively, and 10 (14.3%) and 60 (85.7%) were BCLC stages B and C, respectively. Intrahepatic bile duct (IHD) dilatation was observed in 35 patients (50%). After drainage, the complete response rate was 35.7% (25/70). The mean time to resolution was 17.4 ±8.5 days. However, jaundice was re-aggravated in 74.3% (15/25) after a mean 103.5 ±96.4 days. Multivariate analysis showed that the absence of ascites, presence of IHD dilatation, normal range of prothrombin time, and lower MELD score were significantly associated with complete response. The overall survival rate was 15.7% (11/70) and the median survival time is 28 days (95% confidence interval 2.6-563 days). Complete response and HCC treatment after drainage were significantly associated with survival.
Effective endoscopic biliary drainage is an important palliative treatment in patients with advanced HCC and obstructive jaundice, especially those with IHD dilatation and preserved liver function, as determined by ascites, prothrombin time, and MELD score.
晚期肝细胞癌(HCC)合并黄疸的患者预后极差。尽管胆管引流可解决梗阻性黄疸,但梗阻迹象可能并不明显。本研究评估了内镜下胆管引流在晚期HCC合并梗阻性黄疸患者中的作用。
2010年至2015年,74例患者因晚期HCC导致梗阻性黄疸接受了内镜下胆管引流。黄疸消退定义为完全缓解且总胆红素浓度低于3mg/dl。
74例患者的技术成功率为92.1%(70/76)。在70例成功进行胆管引流的患者中,分别有48例(68.6%)和22例(31.4%)为Child-Pugh B级和C级,分别有10例(14.3%)和60例(85.7%)为BCLC B期和C期。35例患者(50%)观察到肝内胆管(IHD)扩张。引流后,完全缓解率为35.7%(25/70)。消退的平均时间为17.4±8.5天。然而,在平均103.5±96.4天后,74.3%(15/25)的患者黄疸复发。多因素分析显示,无腹水、存在IHD扩张、凝血酶原时间在正常范围以及较低的终末期肝病模型(MELD)评分与完全缓解显著相关。总生存率为15.7%(11/70),中位生存时间为28天(95%置信区间2.6 - 563天)。完全缓解和引流后HCC治疗与生存显著相关。
有效的内镜下胆管引流是晚期HCC合并梗阻性黄疸患者的重要姑息治疗方法,尤其是那些根据腹水、凝血酶原时间和MELD评分确定存在IHD扩张且肝功能保留的患者。